DuPont Decomposition

Why does AJANTPHARM earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

23.3% = 19.4% × 0.89 × 1.36

Latest: FY2026

Profitability

Net Margin

19.4%

21.7% →19.4%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.89x

0.81x →0.89x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.36x

1.24x →1.36x

Assets funded by equity vs debt

Trend Analysis

ROE improved by 1.5 pp over 5 years. Driven by net margin declining (21.7% → 19.4%).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr21.7%0.811.2421.8%
FY20230Cr0Cr15.9%0.791.3817.4%
FY20240Cr0Cr19.6%0.901.3022.9%
FY20250Cr0Cr19.8%0.931.3224.3%
FY20260Cr0Cr19.4%0.891.3623.3%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for AJANTPHARM

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

AJANTPHARM DuPont Analysis — ROE 23.3% | YieldIQ